Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Impact of FDA’s Ranbaxy Ban on Daiichi Sankyo Earnings “Unavoidable”: Mr Sakai
February 3, 2014
- Daiichi Sankyo to Shift to IFRS Starting from FY2013
February 3, 2014
- CSL Behring Launches Hizentra, 1st SC Immunoglobulin Therapy in Japan
February 3, 2014
- Teijin Picks Another Pharma Maven for President
February 3, 2014
- Chugai President Mum on Kadcyla Launch Timing, Price Talks with Regulators Still Ongoing
February 3, 2014
- Chugai Sales Climb 9.6%, Actemra Sales Exceed 100 Billion Yen
February 3, 2014
- Sanofi Demands Payment of $416 Million from Novartis over Dissolved Equa Deal
January 31, 2014
- Novartis Suspected of Drafting Conference Presentation Materials on “Sign” Trial
January 31, 2014
- Novartis Global Net Profit Falls 1%, Japan Sales Drop 15.8%
January 31, 2014
- Maruho to Acquire Distribution Rights for Atopic Dermatitis Drug Protopic from Astellas
January 31, 2014
- Sawai, Nichi-Iko Boosting Annual Production Capacity to 10 Billion Tablets Each in Anticipation of Future Market Growth
January 31, 2014
- Novartis Suspected of Drafting Letter of Consent for “Sign” Trial
January 30, 2014
- Sosei Transfers NorLevo MA Rights to ASKA
January 30, 2014
- Mochida Eyes 10 Billion Yen Generic Biz, Valsartan Combination Drug to Debut in 2014: Pres.
January 29, 2014
- Shionogi Influenza Campaign Causes Stir among Healthcare Professionals
January 29, 2014
- Lurasidone Receives CHMP Positive Opinion: DSP, Takeda
January 29, 2014
- Kenko.com Sues Government over Restriction of Online OTC Drug Sales
January 28, 2014
- Asano Named as New Asahi Kasei President
January 28, 2014
- Zydus to Withdraw from Japan, Discontinuing Shipments by March-End Due to Policy Change of Parent Company
January 28, 2014
- Ajinomoto to Downsize In-House Drug Discovery Research amid Slack Pharma Biz
January 27, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…